Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “GSK”

Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937Completed
NCT05244759Phase 1Updated Feb 17, 2022
Sponsor: Bellus Health Inc. - a GSK company
Healthy
United Kingdom
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughCompleted
NCT04678206Phase 2Updated Dec 13, 2021
Sponsor: Bellus Health Inc. - a GSK company
Refractory Chronic Cough
United States, Canada, Czechia, Germany, Hungary +2 more
Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)Completed
NCT01632241Phase 4Updated Sep 8, 2021
Sponsor: Human Genome Sciences Inc., a GSK Company
Systemic Lupus Erythematosus
United States, Brazil, Colombia, France, South Africa +1 more
A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic CoughTerminated
NCT03979638Phase 2Updated Aug 3, 2021
Sponsor: Bellus Health Inc. - a GSK company
Chronic Refractory Cough
United States, United Kingdom
Efficacy and Safety of Belimumab in Patients With Active Lupus NephritisCompleted
NCT01639339Phase 3Updated Mar 19, 2021
Sponsor: Human Genome Sciences Inc., a GSK Company
Lupus Nephritis
United States, Argentina, Belgium, Brazil, Canada +16 more
Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand EczemaCompleted
NCT00817063Phase 3Updated Apr 27, 2020
Sponsor: Stiefel, a GSK Company
Eczema
United States
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential ThrombocythemiaTerminated
NCT01998828Phase 2Updated Apr 20, 2020
Sponsor: Sierra Oncology LLC - a GSK company
Polycythemia Vera · Essential Thrombocythemia
United States, Australia, Canada, France, Germany
A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057Completed
NCT00712933Phase 3Updated Dec 5, 2019
Sponsor: Human Genome Sciences Inc., a GSK Company
Systemic Lupus Erythematosus
Argentina, Austria, Belgium, Brazil, Canada +23 more
A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02Completed
NCT00583362Phase 2Updated Jul 23, 2019
Sponsor: Human Genome Sciences Inc., a GSK Company
Systemic Lupus Erythematosus
United States, Canada
A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple MyelomaTerminated
NCT00920556Phase 2Updated Feb 27, 2019
Sponsor: Sirtris, a GSK Company
Multiple Myeloma
Denmark, United Kingdom
Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia MyelofibrosisCompleted
NCT01423058Phase 1, Phase 2Updated Feb 4, 2019
Sponsor: Sierra Oncology LLC - a GSK company
Primary Myelofibrosis · Post-Polycythemia Vera · Post-Essential Thrombocythemia Myelofibrosis
United States, Canada
Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)Completed
NCT01236638Phase 2Updated Feb 4, 2019
Sponsor: Sierra Oncology LLC - a GSK company
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
United States, Australia, Canada
Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)Completed
NCT00935987Phase 1, Phase 2Updated Feb 1, 2019
Sponsor: Sierra Oncology LLC - a GSK company
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
United States, Australia, Canada
Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal AdenocarcinomaTerminated
NCT02244489Phase 1Updated Feb 1, 2019
Sponsor: Sierra Oncology LLC - a GSK company
Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
United States
Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in PhaseTerminated
NCT02258607Phase 1Updated Feb 1, 2019
Sponsor: Sierra Oncology LLC - a GSK company
Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer
United States
Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)Terminated
NCT02206763Phase 1Updated Feb 1, 2019
Sponsor: Sierra Oncology LLC - a GSK company
EGFR Mutated EGFR TKI Naive Metastatic NSCLC
United States
A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.Completed
NCT02017899Phase 1Updated Jan 23, 2019
Sponsor: GSK Vaccines Institute For Global Health S.r.l.
Shigellosis
France
Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular CarcinomaCompleted
NCT01258608Phase 1, Phase 2Updated Dec 19, 2018
Sponsor: Human Genome Sciences Inc., a GSK Company
Carcinoma, Hepatocellular
United States, Germany, Poland, Puerto Rico, Romania +2 more
BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food EffectCompleted
NCT03638180Phase 1Updated Nov 9, 2018
Sponsor: Bellus Health Inc. - a GSK company
Cough
Canada
Sexual Function in Men Receiving Dutasteride for Androgenetic AlopeciaCompleted
NCT02014584Phase 3Updated Oct 11, 2018
Sponsor: Stiefel, a GSK Company
Alopecia
Chile, Hong Kong, Singapore, South Korea, Taiwan
Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis PatientsCompleted
NCT00693654Phase 4Updated Sep 10, 2018
Sponsor: Wake Forest University
Pruritis
United States
A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)Completed
NCT01597492Phase 4Updated Aug 16, 2018
Sponsor: Human Genome Sciences Inc., a GSK Company
Systemic Lupus Erythematosus
United States
Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human SubjectsCompleted
NCT00937326Phase 2Updated Jul 13, 2018
Sponsor: Sirtris, a GSK Company
Diabetes Mellitus, Type 2
Bulgaria, Estonia, Hungary, Poland, Romania +3 more
Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.Completed
NCT01323673Phase 4Updated Jun 20, 2018
Sponsor: Stiefel, a GSK Company
Dermatitis, Chronic
United States
A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)Completed
NCT01484496Phase 3Updated Jun 6, 2018
Sponsor: Human Genome Sciences Inc., a GSK Company
Systemic Lupus Erythematosus
United States, Argentina, Austria, Belgium, Brazil +26 more

Previous page Next page